3 Top Biotech Stocks You Shouldn't Ignore
- ByStockNews-
The biotech industry got a huge boost last year as companies scrambled to find treatments and vaccines for COVID-19. After hitting a high in February, the industry fell back as...
The biotech industry got a huge boost last year as companies scrambled to find treatments and vaccines for COVID-19. After hitting a high in February, the industry fell back as...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech Stocks Hitting 52-week Highs April 13)Bio-Techne Corporation (NASDAQ:...
Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in the treatment of adult...
The biotech sector continues to be in focus as the development of vaccines for coronavirus continues to be the key focus. Other pipeline and regulatory updates also grabbed the...
Shares of bluebird bio, Inc. BLUE gained 3.2% after the company and its partner Bristol Myers (NYSE:BMY) Squibb BMY announced that the FDA has approved their chimeric antigen...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Sell | Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Neutral | Buy | Strong Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 238.69 | 241.89 | 237.82 | -0.40 | -0.17% | 14.42M | NYSE | |||
| 342.00 | 345.99 | 321.03 | +19.25 | +5.96% | 22.65M | NASDAQ | |||
| 154.69 | 160.20 | 151.25 | -1.75 | -1.12% | 5.21M | NYSE | |||
| 30.92 | 31.04 | 30.35 | -0.48 | -1.53% | 13.56M | NYSE | |||
| 22.47 | 23.26 | 22.30 | -0.68 | -2.94% | 46.63M | NYSE | |||
| 76.66 | 76.75 | 75.37 | +0.67 | +0.88% | 1.76M | NASDAQ | |||
| 19.28 | 19.48 | 18.90 | -0.40 | -2.03% | 11.84M | NASDAQ | |||
| 27.24 | 27.58 | 25.45 | +1.15 | +4.41% | 50.77M | NASDAQ | |||
| 8.82 | 10.03 | 7.23 | +1.47 | +20.00% | 249.10M | NASDAQ | |||
| 4.18 | 4.19 | 4.13 | +0.05 | +1.21% | 22.91M | NYSE | |||
| 11.14 | 11.32 | 10.81 | +0.020 | +0.18% | 3.11M | NASDAQ | |||
| 16.20 | 17.50 | 11.10 | +3.83 | +30.96% | 19.38M | NASDAQ | |||
| 18.07 | 19.65 | 17.93 | -1.24 | -6.42% | 5.77M | NASDAQ | |||
| 54.42 | 55.08 | 52.62 | +1.29 | +2.43% | 886.77K | NASDAQ | |||
| 5.92 | 6.09 | 5.52 | +0.25 | +4.41% | 664.87K | NASDAQ |
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.